Genetic lesions in chronic lymphocytic leukemia: what's ready for prime time use?

Moreno, Carol; Montserrat, Emili

doi:10.3324/haematol.2009.016873

Cited by 17 publications

(11 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, the median age at diagnosis is 60 years for men and 54 years for women [24][25][26]. The western data showed a median age of approximately 70 years at the time of diagnosis for entire group [27] while in our study 58 years was the median age for the entire group. Our study showed a male preponderance (M:F ratio, 3.3:1) in a study group of 49 patients which was similar to the western data also showing a male preponderance (M:F ratio, 1.7: 1) although the difference between the proportions of the two genders in the western data was considerably less.…”

Section: Discussionsupporting

confidence: 40%

Clinical and Laboratory Parameters in a Cohort of CLL Patient: A Single Centre Experience

Taj¹

2017

HTIJ

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 40%

Clinical and Laboratory Parameters in a Cohort of CLL Patient: A Single Centre Experience

Taj¹

2017

HTIJ

View full text Add to dashboard Cite

show abstract

“…Of these biologic markers, the one that has consistently proved to have the most important effect in CLL is deletion of band 13.1 of the short arm of chromosome 17 (17p-) [3]. 17p-is found in 5-10 % of patients with previously untreated CLL [4]. Patients have an increased likelihood of acquiring abnormalities in chromosome 17 as their disease progresses and after various forms of therapy [5].…”

Section: Introductionmentioning

confidence: 99%

De novo deletion 17p13.1 as a predictor for disease progression in chronic lymphocytic leukemia

et al. 2014

View full text Add to dashboard Cite

To determine the prognostic impact of de novo deletion 17p13.1 (17p-) in previously untreated chronic lymphocytic leukemia (CLL) patients, we prospectively studied the outcome of 71 treatment-naïve CLL patients. About 18.3 % of them had 17p- detected by interphase fluorescent in situ hybridization (FISH) at diagnosis. There was statistically significant difference between 17p- negative and positive patients as regards 2-year overall survival [OS] (89.7 vs. 53.8 %, respectively; P = 0.001). On the other hand, 2-year progression-free survival [PFS] was also significantly higher in 17p- negative group than in 17p- positive one (82.8 vs. 23.1 %, respectively; P < 0.001). On univariate analysis for OS, 17p- positivity was significantly associated with shorter OS (P = 0.003). However, when we performed multivariate analysis, 17p- lost its significant impact. On the other hand, 17p- positivity was a significant risk factor for PFS in both univariate and multivariate analyses [independent risk factor] (P < 0.001 and P = 0.02, respectively). So, 17p- is a predictor for disease progression, but not for survival in CLL patients.

show abstract

“…Several prognostic markers have been already identified such as the expression of non-mutated immunoglobulin heavy variable genes (UM-IgV H ) and high level of 70 kD zeta-associated protein ( ZAP70 ), both associated with unfavorable prognosis [3, 4]. Also, chromosomal alterations are detected in >80% of all CLL cases and can discriminate patients with different outcomes: (i) low risk patients have a normal karyotype or 13q deletion; (ii) intermediate risk patients have 11q deletion or trisomy 12; and (iii) high risk patients have 17p deletion or a complex karyotype [5]. Since many CLL cases show discordant prognostic factors, the identification of new parameters able to relate disease stage and clinical outcome is important for patient management.…”

Section: Characteristics and Outcomes Of Chronic Lymphocytic Leukemiamentioning

confidence: 99%

Novel Mechanisms of Regulation of miRNAs in CLL

et al. 2016

View full text Add to dashboard Cite

B-cell chronic lymphocytic leukemia (CLL) is the most common adult human leukemia. Although, the molecular alterations leading to CLL onset and progression are still under investigation (specifically, the interplay and exact role of oncogenes and tumor suppressors in CLL pathogenesis). MicroRNAs are small non-coding RNAs that regulate gene expression and are expressed in a tissue specific manner. Deregulation of microRNAs can alter expression levels of genes involved in the development and/or progression of tumors. In CLL, microRNAs can function as oncogenes or tumor suppressors. Here, we review the most recent findings on the role of microRNAs in the onset/progression of CLL, and how this knowledge can be used to identify new biomarkers and targets to treat this leukemia.

show abstract

Genetic lesions in chronic lymphocytic leukemia: what's ready for prime time use?

Cited by 17 publications

References 30 publications

Clinical and Laboratory Parameters in a Cohort of CLL Patient: A Single Centre Experience

Clinical and Laboratory Parameters in a Cohort of CLL Patient: A Single Centre Experience

De novo deletion 17p13.1 as a predictor for disease progression in chronic lymphocytic leukemia

Novel Mechanisms of Regulation of miRNAs in CLL

Contact Info

Product

Resources

About